Literature DB >> 17680841

Comparison of the effects of travoprost, latanoprost and bimatoprost on ocular circulation: a 6-month clinical trial.

Ozlem Gurbuz Koz1, Arzu Ozsoy, Alper Yarangumeli, S Kenan Kose, Gulcan Kural.   

Abstract

PURPOSE: To study the effect of three prostaglandin F(2)-alpha (PG) analogues on retrobulbar blood flow velocity in previously untreated patients with primary open-angle glaucoma (POAG) or ocular hypertension (OHT), using colour Doppler ultrasound.
METHODS: Sixty newly diagnosed patients with POAG or OHT were randomly assigned to travoprost 0.004% (n = 12 with POAG, n = 8 with OHT), latanoprost 0.005% (n = 11 with POAG, n = 9 with OHT) and bimatoprost 0.03% (n = 13 with POAG, n = 7 with OHT) treatment groups in a double-masked fashion. At baseline examination, blood pressure, heart rate and intraocular pressure (IOP) were recorded. Peak-systolic and end-diastolic velocities were measured in the ophthalmic (OA), central retinal (CRA) and temporal short posterior ciliary arteries (PCA). The resistive index (RI) and ocular perfusion pressure (OPP) were determined for each treatment group. After a treatment period of 6-months, all procedures were repeated.
RESULTS: There were no significant differences in age (53 +/- 14 years in the travoprost group, 51 +/- 14 years in the latanoprost group, 53 +/- 11 years in the bimatoprost group), gender (11 men, nine women; 11 men, nine women; 13 men, seven women, by group, respectively), or clinical diagnosis (POAG or OHT) among treatment groups (p > 0.05). A significant decrease in IOP (baseline: 26.4 +/- 3.3 mmHg, 26.8 +/- 1.3 mmHg, 25.8 +/- 1.8 mmHg, respectively; month 6: 20.9 +/- 1.9 mmHg, 20.8 +/- 2.4 mmHg, 18.3 +/- 1.2 mmHg, respectively; p < 0.0001) and an increase in OPP (baseline: 33.7 +/- 3.8 mmHg, 33.5 +/- 3.2 mmHg, 33.9 +/- 2.6 mmHg, respectively; month 6: 40.2 +/- 3.5 mmHg, 39.9 +/- 3.1 mmHg, 41.7 +/- 2.6 mmHg, respectively; p < 0.0001) were verified in all three groups during the study period. Mean baseline RI values for the CRA in the travoprost group and the OA in the latanoprost group were both 0.7 +/- 0.1 mmHg and both values were statistically significantly lower at 6 months (0.6 +/- 0.1 mmHg in both groups; p = 0.002, p < 0.0001, respectively). In the bimatoprost group there was no statistically significant difference in haemodynamic parameters over the study period (p > 0.05).
CONCLUSIONS: Our results suggest that the three PG analogues significantly reduce IOP and increase OPP in patients with POAG or OHT. Topical travoprost and latanoprost significantly reduce the RI of the CRA and OA, respectively. We were unable to determine any effect of topical bimatoprost on ocular haemodynamics.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17680841     DOI: 10.1111/j.1600-0420.2007.00960.x

Source DB:  PubMed          Journal:  Acta Ophthalmol Scand        ISSN: 1395-3907


  16 in total

Review 1.  Effects of travoprost in the treatment of open-angle glaucoma or ocular hypertension: A systematic review and meta-analysis.

Authors:  Jin-Wei Cheng; Gui-Lin Xi; Rui-Li Wei; Ji-Ping Cai; You Li
Journal:  Curr Ther Res Clin Exp       Date:  2009-08

2.  Intraocular pressure, blood pressure, and retinal blood flow autoregulation: a mathematical model to clarify their relationship and clinical relevance.

Authors:  Giovanna Guidoboni; Alon Harris; Simone Cassani; Julia Arciero; Brent Siesky; Annahita Amireskandari; Leslie Tobe; Patrick Egan; Ingrida Januleviciene; Joshua Park
Journal:  Invest Ophthalmol Vis Sci       Date:  2014-05-29       Impact factor: 4.799

3.  Clinical utility and differential effects of prostaglandin analogs in the management of raised intraocular pressure and ocular hypertension.

Authors:  Anne J Lee; Peter McCluskey
Journal:  Clin Ophthalmol       Date:  2010-07-30

4.  Effect of travoprost on 24-hour intraocular pressure in normal tension glaucoma.

Authors:  Yuya Nomura; Shunsuke Nakakura; Mitsuyasu Moriwaki; Yasuhiro Takahashi; Kunihiko Shiraki
Journal:  Clin Ophthalmol       Date:  2010-07-30

5.  Does the intraocular pressure-lowering effect of prostaglandin analogues continue over the long term?

Authors:  Caner Kara; Emine Malkoç Şen; Kadriye Ufuk Elgin; Kurtuluş Serdar; Pelin Yilmazbaş
Journal:  Int Ophthalmol       Date:  2016-08-09       Impact factor: 2.031

6.  Targeted delivery of antiglaucoma drugs to the supraciliary space using microneedles.

Authors:  Yoo C Kim; Henry F Edelhauser; Mark R Prausnitz
Journal:  Invest Ophthalmol Vis Sci       Date:  2014-09-11       Impact factor: 4.799

7.  The diurnal and nocturnal effect of travoprost with sofZia on intraocular pressure and ocular perfusion pressure.

Authors:  Leonard K Seibold; Malik Y Kahook
Journal:  Am J Ophthalmol       Date:  2013-10-30       Impact factor: 5.258

8.  Ocular blood flow as a clinical observation: Value, limitations and data analysis.

Authors:  Alon Harris; Giovanna Guidoboni; Brent Siesky; Sunu Mathew; Alice C Verticchio Vercellin; Lucas Rowe; Julia Arciero
Journal:  Prog Retin Eye Res       Date:  2020-01-24       Impact factor: 21.198

9.  Daily costs of prostaglandin analogues as monotherapy or in fixed combinations with timolol, in Denmark, Finland, Germany and Sweden.

Authors:  Anders Bergström; Frédérique Maurel; Claude Le Pen; Emilie Lamure; Michael Kent; Isabelle Bardoulat; Gilles Berdeaux
Journal:  Clin Ophthalmol       Date:  2009-08-20

10.  Efficacy and safety of prostaglandin analogues in patients with predominantly primary open-angle glaucoma or ocular hypertension: a meta-analysis.

Authors:  Oghenowede Eyawo; Jean Nachega; Pierre Lefebvre; David Meyer; Beth Rachlis; Chia-Wen Lee; Steven Kelly; Edward Mills
Journal:  Clin Ophthalmol       Date:  2009-08-03
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.